GlobeNewswire, Inc.

Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix® was generally well tolerated with a safety...

Government of Slovenia

SLOVENIA, October 28 - When governments gather in Yerevan from 19 to 30 October for the 17th Conference of the Parties to the Convention on Biological Diversity, they will face a simple but hard question: are we keeping the promises we made?

GlobeNewswire, Inc.

Stellantis Reports Q3 2026 Financial Results FaSTLAne 2030 Execution Continues, with All Financial Metrics Improved Year-over-Year; Guidance Reaffirmed, Value Creation Program Ramping Up Net revenues increased to €37.6 billion, up 1.0% versus Q3...

GlobeNewswire, Inc.

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned...

GlobeNewswire, Inc.

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements...

GlobeNewswire, Inc.

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal...